Inverse correlation between Interleukin-34 and gastric cancer, a potential biomarker for prognosis

Abstract Background Gastric cancer (GC) is a malignancy with high morbidity/mortality, partly due to a lack of reliable biomarkers for early diagnosis. It is important to develop reliable biomarker(s) with specificity, sensitivity and convenience for early diagnosis. The role of tumour-associated macrophages (TAMs) and survival of GC patients are controversial. Macrophage colony stimulating factor (MCSF) regulates monocytes/macrophages. Elevated MCSF is correlated with invasion, metastasis and poor survival of tumour patients. IL-34, a ligand of the MCSF receptor, acts as a “twin” to MCSF, demonstrating overlapping and complimentary actions. IL-34 involvement in tumours is controversial, possibly due to the levels of MCSF receptors. While the IL34/MCSF/MCSFR axis is very important for regulating macrophage differentiation, the specific interplay between these cytokines, macrophages and tumour development is unclear.Methods A multi-factorial evaluation could provide more objective utility, particularly for either prediction and/or prognosis of gastric cancer. Precision medicine requires molecular diagnosis to determine the specifically mutant function of tumours, and is becoming popular in the treatment of malignancy. Therefore, elucidating specific molecular signalling pathways in specific cancers facilitates the success of a precision medicine approach. Gastric cancer tissue arrays were generated from stomach samples with TNM stage, invasion depth and the demography of these patients (n = 185). Using immunohistochemistry/histopathology, MCSF, IL-34 and macrophages were determined.Results We found that IL-34 may serve as a predictive biomarker, but not as an independent, prognostic factor in GC; MCSF inversely correlated with survival of GC in TNM III‑IV subtypes. Increased CD68+TAMs were a good prognostic factor in some cases and could be used as an independent prognostic factor in male T3 stage GC.Conclusion Our data support the potency of IL-34, MCSF, TAMs and the combination of IL34/TAMs as novel biological markers for GC, and may provide new insight for both diagnosis and cellular therapy of GC.

Download Full-text

Inverse correlation between Interleukin-34 and gastric cancer, a potential biomarker for prognosis

10.21203/rs.3.rs-26741/v2 ◽

2020 ◽

Author(s):

Qinghua Liu ◽

Ying Zhang ◽

Jiwei Zhang ◽

Kun Tao ◽

Brett D Hambly ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Early Diagnosis ◽

Precision Medicine ◽

Cellular Therapy ◽

Inverse Correlation ◽

Independent Prognostic Factor ◽

Cancer Tissue ◽

High Morbidity ◽

Potential Biomarker

Abstract Background : Gastric cancer (GC) is a malignancy with high morbidity/mortality, partly due to a lack of reliable biomarkers for early diagnosis. It is important to develop reliable biomarker(s) with specificity, sensitivity and convenience for early diagnosis. The role of tumour-associated macrophages (TAMs) and survival of GC patients are controversial. Macrophage colony stimulating factor (MCSF) regulates monocytes/macrophages. Elevated MCSF is correlated with invasion, metastasis and poor survival of tumour patients. IL-34, a ligand of the MCSF receptor, acts as a “twin” to MCSF, demonstrating overlapping and complimentary actions. IL-34 involvement in tumours is controversial, possibly due to the levels of MCSF receptors. While the IL‑34/MCSF/MCSFR axis is very important for regulating macrophage differentiation, the specific interplay between these cytokines, macrophages and tumour development is unclear. Methods : A multi-factorial evaluation could provide more objective utility, particularly for either prediction and/or prognosis of gastric cancer. Precision medicine requires molecular diagnosis to determine the specifically mutant function of tumours, and is becoming popular in the treatment of malignancy. Therefore, elucidating specific molecular signalling pathways in specific cancers facilitates the success of a precision medicine approach. Gastric cancer tissue arrays were generated from stomach samples with TNM stage, invasion depth and the demography of these patients (n=185). Using immunohistochemistry/histopathology, MCSF, IL-34 and macrophages were determined. Results : We found that IL-34 may serve as a predictive biomarker, but not as an independent, prognostic factor in GC; MCSF inversely correlated with survival of GC in TNM III‑IV subtypes. Increased CD68 + TAMs were a good prognostic factor in some cases and could be used as an independent prognostic factor in male T3 stage GC. Conclusion : Our data support the potency of IL-34, MCSF, TAMs and the combination of IL‑34/TAMs as novel biological markers for GC, and may provide new insight for both diagnosis and cellular therapy of GC.

Download Full-text

HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer

Digestive Diseases and Sciences ◽

10.1007/s10620-005-9057-1 ◽

2006 ◽

Vol 51 (8) ◽

pp. 1371-1379 ◽

Cited By ~ 184

Author(s):

Dong Il Park ◽

Jung Won Yun ◽

Jung Ho Park ◽

Suk Joong Oh ◽

Hong Joo Kim ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Independent Prognostic Factor ◽

Her 2

Download Full-text

Preoperative Plasma Fibrinogen and Serum Albumin Score Is an Independent Prognostic Factor for Resectable Stage II-III Gastric Cancer

Disease Markers ◽

10.1155/2019/9060845 ◽

2019 ◽

Vol 2019 ◽

pp. 1-10 ◽

Cited By ~ 2

Author(s):

Menghui Wu ◽

Yuchen Pan ◽

Zhifang Jia ◽

Yueqi Wang ◽

Na Yang ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Serum Albumin ◽

Poor Prognosis ◽

Response Rate ◽

Prognostic Significance ◽

Independent Prognostic Factor ◽

The Other ◽

Plasma Fibrinogen ◽

Radical Gastrectomy

Background. Radical gastrectomy with D2 lymphadenectomy is recognized as the standard treatment for resectable advanced gastric cancer. Preoperative fibrinogen and albumin measurements may bring clinical benefits in terms of providing advanced notice of a poor prognosis or recurrence in patients undergoing radical resection. The aim of this study was to identify markers that are predictive of a poor prognosis prior to surgery. Methods. Eight hundred forty-two consecutive patients who underwent curative radical gastrectomy at our hospital between 2008 and 2012 were retrospectively reviewed. Based on plasma fibrinogen and serum albumin levels, preoperative fibrinogen and albumin scores (Fib-Alb scores) were investigated, and the prognostic significance was determined. Results. The patients were classified according to a Fib-Alb score of 0 (n=376), 1 (n=327), or 2 (n=139). When the correlation between the response rate and the change in the Fib-Alb score was investigated, the response rate was significantly lower in patients with an increased Fib-Alb score than in the other patients. In the survival analysis, patients in the Fib-Alb high-score group exhibited significantly worse recurrence-free survival (RFS) (P=0.030) than patients in the other groups. A multivariate analysis using clinical stage and the change in the Fib-Alb score as covariates revealed that a change in the Fib-Alb score (Fib-Alb score 1, HR: 1.31, 95% CI: 1.03-1.66, P=0.028; Fib-Alb score 2, HR: 1.61, 95% CI: 1.20-2.17, P=0.001) was a significant independent predictive factor for RFS. Conclusions. The prognosis of patients with high fibrinogen and low albumin levels is poor. The Fib-Alb score was shown to be an independent prognostic factor for postoperative recurrence in gastric cancer patients who underwent radical gastrectomy.

Download Full-text

ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer

Pathology - Research and Practice ◽

10.1016/j.prp.2020.153032 ◽

2020 ◽

Vol 216 (8) ◽

pp. 153032

Author(s):

Lei Sun ◽

Run-Chang Wang ◽

Qing Zhang ◽

Lin-Lang Guo

Keyword(s):

Endometrial Cancer ◽

Prognostic Factor ◽

Immune Checkpoint ◽

Independent Prognostic Factor ◽

Potential Biomarker

Download Full-text

Exosomal miR-1246 in serum as a potential biomarker for early diagnosis of gastric cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-019-01532-9 ◽

2019 ◽

Vol 25 (1) ◽

pp. 89-99 ◽

Cited By ~ 9

Author(s):

Yuntao Shi ◽

Zhonghong Wang ◽

Xiaojuan Zhu ◽

Ling Chen ◽

Yilan Ma ◽

...

Keyword(s):

Gastric Cancer ◽

Early Diagnosis ◽

Potential Biomarker

Download Full-text

Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis

Medical Oncology ◽

10.1007/s12032-014-0015-7 ◽

2014 ◽

Vol 31 (7) ◽

Cited By ~ 14

Author(s):

Wenzhang Fang ◽

Hongmei Cui ◽

Danyang Yu ◽

Ying Chen ◽

Jiejun Wang ◽

...

Keyword(s):

Gastric Cancer ◽

Lymph Node ◽

Prognostic Factor ◽

Lymph Node Metastasis ◽

Independent Prognostic Factor ◽

Human Gastric Cancer ◽

Acetyl Coa Carboxylase ◽

Acetyl Coa ◽

Node Metastasis

Download Full-text

126 POSTER The ratio between metastatic and examined lymph nodes (N-ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1,853 patients

European Journal of Surgical Oncology ◽

10.1016/s0748-7983(06)70561-3 ◽

2006 ◽

Vol 32 ◽

pp. S38

Author(s):

S. Mocellin ◽

A. Marchet ◽

A. Ambrosi ◽

P. Morgagni ◽

F. Roviello ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Lymph Nodes ◽

Independent Prognostic Factor ◽

Multicentric Study

Download Full-text

Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer with curative resection.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4121 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4121-4121 ◽

Cited By ~ 1

Author(s):

S. Kang ◽

J. Choi ◽

M. Ahn ◽

H. Lee ◽

S. Han ◽

...

Keyword(s):

Gastric Cancer ◽

Helicobacter Pylori ◽

Prognostic Factor ◽

Advanced Gastric Cancer ◽

Curative Resection ◽

Locally Advanced ◽

Independent Prognostic Factor ◽

Helicobacter Pylori Infection ◽

Locally Advanced Gastric Cancer

Download Full-text

C-reactive protein as an independent prognostic factor for metastatic gastric cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.4_suppl.110 ◽

2013 ◽

Vol 31 (4_suppl) ◽

pp. 110-110 ◽

Cited By ~ 1

Author(s):

Mika Kitagawa ◽

Takaya Shimura ◽

Tomonori Yamada ◽

Keisuke Itoh ◽

Chihiro Hasegawa ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factor ◽

Progression Free Survival ◽

Metastatic Gastric Cancer ◽

Independent Prognostic Factor ◽

C Reactive Protein ◽

Antitumor Effects ◽

Eligibility Criteria ◽

Reactive Protein ◽

Serum Crp

110 Background: S-1 plus cisplatin has been recognized as the standard chemotherapy for metastatic gastric cancer (MGC). Inflammation is considered to be a critical component of tumor progression. C-reactive protein (CRP) has been associated with the development of many cancers, but the significance of CRP remains unclear for MGC. The present study assessed the relationship between serum levels CRP and antitumor effects in MGC. Methods: Among 109 MGC patients who received S-1 plus cisplatin as first-line chemotherapy from January 2006 to December 2011 in 3 Japanese institutions, we retrospectively identified 70 patients who fulfilled eligibility criteria of this study. Patients were categorized into 2 groups depending on serum CRP level before chemotherapy: 43 patients with CRP <1.0 mg/dl (CRP <1.0 group) and 27 patients with CRP ≥1.0 mg/dl (CRP ≥1.0 group). Results: Median overall survival was significantly shorter in the CRP ≥1.0 group than in the CRP <1.0 group [267 days (95% CI, 208 to 326) versus 416 days (95% CI, 325 to 507); p = 0.0007]. Moreover, progression-free survival (PFS) was significantly shorter in the CRP ≥1.0 group than in the CRP <1.0 group (median PFS 126 days [95% CI, 63 to 189) versus 188 days (95% CI, 159 to 217); p = 0.0050]. Meanwhile, response rate was determined in 58 patients with target lesions. No significant differences were noted between the CRP <1.0 group and the CRP ≥1.0 group (10/33, 30.3% versus 7/25, 28.0%; p = 0.663). In a multivariate analysis, serum CRP level before chemotherapy was an only independent prognostic factor for MGC (hazard ratio 3.09 (95% CI, 1.46 to 6.54); p = 0.003). Conclusions: Serum CRP level before chemotherapy might be an independent and potential prognostic factor for MGC. Stringent follow-up during chemotherapy is expected for patients with MGC and a high CRP level.

Download Full-text